bioMérieux S.A. (BIM.PA) Stock Analysis & Winston Score

bioMérieux is a French healthcare company that makes machines and test kits used to detect infections and diseases in patients. Its main products are diagnostic systems that identify bacteria, viruses, and other pathogens in blood, urine, and tissue samples. Hospitals, clinical labs, and food safety companies around the world are its primary customers. The company earns most of its revenue by selling both the diagnostic instruments and the consumable reagents and test kits that run on those machines — a model where customers keep buying supplies repeatedly once they own the equipment. bioMérieux operates in over 160 countries and generates roughly half its sales in Europe, with significant business in North America and Asia. Its installed base of instruments creates switching costs that make it hard for hospitals to change suppliers, which is a key competitive advantage. The main risk is that revenue from COVID-related testing has declined sharply, and the company must grow its core infectious disease and industrial testing segments to offset that headwind.